HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Heron Therapeutics (HRTX) PT Raised to $66 at Needham & Company
June 21, 2018 3:48 PM EDTNeedham & Company raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $66.00 (from $42.00) while maintaining a Buy rating.
Analyst Serge Belanger commented, "HRTX reported positive results from two Phase 2b studies in total knee arthroplasty (TKA) and breast augmentation where HTX-011 successfully... More
Heron Therapeutics (HRTX) PT Raised to $54 at Cowen; Sees HTX-011 as $1B+ Opportunity
June 21, 2018 1:15 PM EDTCowen raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $54.00 (from $48.00) while maintaining an Outperform rating after the company announced positive Phase IIb data in TKA and breast augmentation demonstrating superior pain control and opioid reduction compared to placebo and generic bupivacaine. In addition HTX-011... More
Heron Therapeutics (HRTX) PT Raised to $51 at Jefferies
June 21, 2018 11:39 AM EDTJefferies raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $51.00 (from $38.00) while maintaining a Buy rating.
... MoreTwo More Positive HTX-011 Studies Supports Bullish Heron Therapeutics (HRTX) Thesis - Cantor Fitzgerald
June 21, 2018 10:47 AM EDTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $40 price target on Heron Therapeutics (NASDAQ: HRTX) announced positive top-line results from two additional studies which will support the NDA filing for HTX-011 and expand the commercial opportunity for the drug.
"This... More
Heron Therapeutics (HRTX) PT Raised to 'Street High' $80 at Evercore ISI
June 21, 2018 10:23 AM EDTEvercore ISI raised its price target on Heron Therapeutics (NASDAQ: HRTX) to a 'Street High' $80.00 (from $56.00) while maintaining an Outperform rating.
Analyst Josh Schimmer with the rating news.
... More